ZYNLONTA combo trials in r/r DLBCL, key LOTIS-5 data Q2 2026, strong ORR/CR, cash to 2028—read now. Click for this ADCT ...
Non-Hodgkin lymphoma (NHL) is a group of hematologic malignancies that originate from lymphocytes known as B or T cells. This ...
9Honey Celebrity on MSN
'Looked like I was on the way out': Sam Neill reveals he came close to death as he gives huge cancer update
Sam Neill has revealed he came close to death during his long battle with a type of lymphoma but is now cancer-free after ...
Single agent duvelisib demonstrated clinically meaningful response rates, including a substantial proportion of complete responses, in a heavily ...
After being diagnosed with hypothyroidism, I was given a daily pill and sent on my way. But the problems continued. I started ...
A research team at the University of Cologne's Center for Molecular Medicine Cologne (CMMC) has discovered that the protein ...
ZUMA-2 cohorts drive brexu-cel’s journey in relapsed/refractory mantle cell lymphoma, from high response rates to dose ...
Explore how BTK resistance drives poor outcomes in relapsed mantle cell lymphoma and why ZUMA-2 CAR T therapy emerges as a ...
The BRUIN CLL-322 trial evaluated the safety and efficacy of pirtobrutinib plus venetoclax and rituximab in previously treated CLL/SLL patients.
"For these patients, current therapies do not always deliver durable responses, highlighting the urgent need for evidence-based options that can meaningfully extend and improve their lives." ...
Dylan's choices for therapy, as he relapsed, were limited. In fact, there were none.”— Muhammad Bilal Abid, M.D.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results